Welcome to the inaugural issue of the MedInvest newsletter, which will be published monthly – with occasional special bi-weekly issues – going forward. The newsletter will feature articles, going forward, on key developments in private and public biotech and academia, as well as analysis of the biotech market, legal corner, and executive coaches corner. The company plans to launch a TV show in 1Q2021.
MedInvest (MI) was launched by the former conference leaders of the 15 year old OneMed and the conference team of National Foundation for Cancer Research in 4Q2019 to be the leading media company in the life science space. MedInvest publishes a newsletter on biotech news and markets, as well as throwing indication specific investor events in all verticals of biotech except oncology. These event, for the foreseeable future, will be hosted virtually.
In June, MedInvest brought together leading academics, startup and big pharma executives, government scientists and funders, family offices and foundations, and venture and public market funds, to host an event focused on infectious disease. A core goal of this meeting was to create information sharing among all these groups in order to advance treatments and diagnostics for COVID-19, as well as to help infectious disease companies source funding to advance their projects.
The event featured 41 presenting companies, nearly 200 registered investors, and a host of key opinion leaders featured talks, including: Dr. Jerome Kim (Director General of the International Vaccine Institute), Brian Lelyand-Jones (Director Darwin Institute, CMO NFCR, Frm Director McGill and Emory Cancer Centers), Dr. George Poste (Professor, ASU; Former Head of R&D, GSK; Defense Science Board of the U.S. Department of Defense), Dr. Arturo Casadevall (Chair, Molecular Microbiology & Immunology, Johns Hopkins), Dr. Robert Gallo (Co-Founder and Director, The Institute of Human Virology (IHV) and Co-Founder HIV Virus), Dr. Wolfgang Klietman (Harvard Medical School, Co-Founder of the Rabbi’s Vaccine), Dr. Wendy Ziai (Medical Director, Neurovascular Laboratory, Johns Hopkins; Co-Director, Johns Hopkins Bayview Neurocritical Care Unit), Dr. Alfred Slanetz ((CEO Geneius Biotech, Frm CEO Bluebird Bio, Frm Director Product Development Genetech), Dr. Lynda Chin (Founder, Department of Genomic Medicine at MD Anderson Cancer Center; Co-Founder & CEO, Apricity Health), and Doug Monticciolo (Founder, CEO, and CIO of Brevet Capital). The talks are still available here: http://jlrcap.com/MedInvest/
On September 8-10, MedInvest will host a virtual meeting focused on AI and Big Data in biotech and healthcare, as well as digital health. The event is expected to draw 200-250 investors, 40-50 presenting companies, and will feature a virtual partnering system. Current confirmed speakers include: Ray Chauncey (Former Director, IBM Watson Labs; CTO Apricity Health), Abe Heifets (Co-founder & CEO, AtomWise), Nicholas Kelley (Chief Digital Officer / Global Director Data Science and A.I. Innovation, Novartis), Andrew Robertson (Global Head of Strategy and Transformation, Digital and Data Sciences, Sanofi), Lili Gil Valletta (CEO, CEIN+; Former Director of Multicultural Marketing at J&J), Dr. Lynda Chin (Founding Chair, Department of Genomic Medicine, MD Anderson, CEO of Apricity Health), Fred Nazem (Former CEO/Chairman of Oxford Health), and many others. We invite you to register to present (if a company) or attend (if an investor or government official) at https://www.medinvestconferences.com/register.
Comments